HC Wainwright Predicts Gossamer Bio FY2030 Earnings

Gossamer Bio, Inc. (NASDAQ:GOSS) – Stock analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of Gossamer Bio in a research report issued to clients and investors on Tuesday, February 10th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings per share of $0.78 for the year. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share.

A number of other brokerages also recently commented on GOSS. Barclays assumed coverage on shares of Gossamer Bio in a research report on Tuesday, January 27th. They set an “overweight” rating and a $9.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Gossamer Bio in a report on Thursday, January 22nd. Finally, Wall Street Zen downgraded shares of Gossamer Bio from a “hold” rating to a “sell” rating in a research note on Friday, January 23rd. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $8.60.

Gossamer Bio Price Performance

Shares of GOSS opened at $2.35 on Thursday. The business’s 50-day moving average is $2.90 and its 200-day moving average is $2.67. The company has a market capitalization of $543.92 million, a price-to-earnings ratio of -3.41 and a beta of 1.93. Gossamer Bio has a fifty-two week low of $0.76 and a fifty-two week high of $3.87.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of GOSS. Janney Montgomery Scott LLC bought a new stake in Gossamer Bio in the fourth quarter worth $39,000. Deutsche Bank AG boosted its stake in shares of Gossamer Bio by 0.4% during the 4th quarter. Deutsche Bank AG now owns 1,284,335 shares of the company’s stock worth $3,981,000 after acquiring an additional 5,414 shares in the last quarter. Cerity Partners LLC increased its holdings in shares of Gossamer Bio by 39.7% during the 4th quarter. Cerity Partners LLC now owns 31,914 shares of the company’s stock valued at $99,000 after acquiring an additional 9,075 shares during the last quarter. O Shaughnessy Asset Management LLC bought a new position in shares of Gossamer Bio in the 4th quarter valued at approximately $41,000. Finally, Goldman Sachs Group Inc. lifted its holdings in Gossamer Bio by 498.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,792,114 shares of the company’s stock worth $5,556,000 after purchasing an additional 1,492,532 shares during the last quarter. Institutional investors own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.